Skip to main content

Tumor Suppressor Genes

  • Chapter
Basic Science of Cancer

Abstract

Tumor suppressor genes (TSGs) are genes whose protein products function in the control of cellular proliferation. In contrast to oncogenes, which are activated in cancer, TSGs are functionally inactivated in cancer. In general, TSGs are characterized by loss-offunction mutations in human tumors. These loss-of-fuunction mutations can be missense mutations that alter critical amino acid residues, mutations that cause premature protein truncation resulting in the loss of functional domains or unstable products, or deletion of the entire gene. Loss-of-function mutations are often accompanied by loss of heterozygosity (LOH) at the TSG locus; LOH can be detected by comparing the pattern of a polymorphic DNA marker in tumor versus normal DNA (see Chapter 1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Knudson A: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68: 820–823.

    Article  PubMed  Google Scholar 

  2. Clurman B, Groudine M: Defining tumour-suppressor genes. Nature 1997, 389: 123.

    Article  CAS  Google Scholar 

  3. Haber D, Harlow E: Tumour-suppressor genes: evolving definitions in the genomic age. Nat Genet 1997, 16: 320–322.

    Article  PubMed  CAS  Google Scholar 

  4. Knudson A: Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993, 90: 10914–10921.

    Article  PubMed  CAS  Google Scholar 

  5. Neumann H, Lips C, Hsia Y, Thar B: Von HippelLindau syndrome. Brain Patho11995, 5: 181–193.

    Google Scholar 

  6. Prowse A, Webster A, Richards F,: Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 1997, 60: 765–771.

    PubMed  CAS  Google Scholar 

  7. Foster K, Prowse A, van den Berg A,: Somatic mutations of the von Hippel-Lindau disease TSG in non-familial clear cell renal carcinoma. Hum Mol Genet 1994, 3: 2169–2173.

    Article  PubMed  CAS  Google Scholar 

  8. Fearon E, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990, 61: 759–767.

    Article  PubMed  CAS  Google Scholar 

  9. Kinzler K, Vogelstein B: Gatekeepers and caretakers. Nature 1997, 386: 761–763.

    Article  PubMed  CAS  Google Scholar 

  10. Moslein G, Tester D, Lindor N,: Microsatellite instability and mutation analysis of hMSH2 and HMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 1996, 5: 1245–1252.

    Article  PubMed  CAS  Google Scholar 

  11. Neumann H, Bender B: Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med 1998, 243: 541–545.

    Article  PubMed  CAS  Google Scholar 

  12. Spirio L, Olschwant S, Groden J,: Alleles of the APC gene: an attenuated form of familial polyposis. Cell 1993, 75: 951–957.

    Article  PubMed  CAS  Google Scholar 

  13. Gutmann D, Geist R, Xu H,: Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet 1998, 7: 335–345.

    Article  PubMed  CAS  Google Scholar 

  14. Lin S-C, Skapek S, Lee E-H: Genes in the RB pathway and their knockout in mice. Semin Cancer Biol 1996, 7: 279–289.

    Article  PubMed  CAS  Google Scholar 

  15. Jacks T, Weinberg R: The expanding role of cell cycle regulators. Science 1998, 280: 1035.

    Article  PubMed  CAS  Google Scholar 

  16. Hesketh R: The Oncogene and Tumor Suppressor Gene Facts Book. San Diego, CA: Academic Press; 1997.

    Google Scholar 

  17. Chin L, Pomerantz J, DePinho R: The INK4a/ARF tumor suppressor: one gene, two products, two pathways. TIBS 1998, 23: 291.

    PubMed  CAS  Google Scholar 

  18. Helin K, Peters G: Tumor suppressors: from genes to function and possible therapies. Trends Genet 1998, 14: 8–9.

    Article  PubMed  CAS  Google Scholar 

  19. Reynisdottir I, Polyak K, Iavarone A, Masague J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-5. Genes Dey 1995, 9: 1931–1945.

    Google Scholar 

  20. Kolodner R: Mismatch repair: mechanisms and relationship to cancer susceptibility. TIBS 1995, 20: 397.

    PubMed  CAS  Google Scholar 

  21. Kolodner R: Biochemistry and genetics of eukaryotic mismatch repair. Genes Dey 1996, 10: 1433–1442.

    Article  CAS  Google Scholar 

  22. Prolla T, Abruin A, Bradley A: DNA mismatch repair deficient mice in cancer research. Semin Cancer Biol 1996, 7: 241–247.

    Article  PubMed  CAS  Google Scholar 

  23. Karran P: Appropriate partners make good matches. Science 1995, 268: 1857.

    Article  PubMed  CAS  Google Scholar 

  24. Kunkel T, Resnick M, Gordenin D: Mutators specificity and disease: looking over the FENce. Cell 1997, 88: 155–158.

    Article  PubMed  CAS  Google Scholar 

  25. Marsischky G, Filosi M, Kane M, Kolodner R: Redundancy of saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dey 1996, 10: 407–429.

    Article  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Current Medicine, Inc.

About this chapter

Cite this chapter

Plank, T.L., Henske, E.P. (2000). Tumor Suppressor Genes. In: Kruh, G.D., Tew, K.D. (eds) Basic Science of Cancer. Current Medicine Group. https://doi.org/10.1007/978-1-4684-8437-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-8437-3_3

  • Publisher Name: Current Medicine Group

  • Print ISBN: 978-1-4684-8439-7

  • Online ISBN: 978-1-4684-8437-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics